JP2015516983A - Ｐａｒ４アゴニストペプチド - Google Patents

Ｐａｒ４アゴニストペプチド Download PDF

Info

Publication number
JP2015516983A
JP2015516983A JP2015509095A JP2015509095A JP2015516983A JP 2015516983 A JP2015516983 A JP 2015516983A JP 2015509095 A JP2015509095 A JP 2015509095A JP 2015509095 A JP2015509095 A JP 2015509095A JP 2015516983 A JP2015516983 A JP 2015516983A
Authority
JP
Japan
Prior art keywords
mmol
peptide
par4
amino acid
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015509095A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015516983A5 (enExample
Inventor
マイケル・ジー・コーナッカー
クラウディオ・マペッリ
ダグラス・ジェイムズ・リーキシンガー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of JP2015516983A publication Critical patent/JP2015516983A/ja
Publication of JP2015516983A5 publication Critical patent/JP2015516983A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
JP2015509095A 2012-04-26 2013-04-24 Ｐａｒ４アゴニストペプチド Pending JP2015516983A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261638577P 2012-04-26 2012-04-26
US61/638,577 2012-04-26
US201361781538P 2013-03-14 2013-03-14
US61/781,538 2013-03-14
PCT/US2013/037897 WO2013163248A1 (en) 2012-04-26 2013-04-24 Par4 agonist peptides

Publications (2)

Publication Number Publication Date
JP2015516983A true JP2015516983A (ja) 2015-06-18
JP2015516983A5 JP2015516983A5 (enExample) 2015-08-20

Family

ID=48289680

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015509095A Pending JP2015516983A (ja) 2012-04-26 2013-04-24 Ｐａｒ４アゴニストペプチド

Country Status (9)

Country Link
US (3) US8927688B2 (enExample)
EP (1) EP2841448A1 (enExample)
JP (1) JP2015516983A (enExample)
CN (1) CN104411713A (enExample)
BR (1) BR112014026644A2 (enExample)
CA (1) CA2871640A1 (enExample)
EA (1) EA201491959A1 (enExample)
MX (1) MX2014012803A (enExample)
WO (1) WO2013163248A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015514808A (ja) * 2012-04-26 2015-05-21 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 血小板凝集を治療するためのプロテアーゼ活性化受容体４（ｐａｒ４）阻害剤としてのイミダゾチアジアゾールおよびイミダゾピラジン誘導体

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015061733A1 (en) * 2013-10-25 2015-04-30 Bristol-Meyers Squibb Company Diagnostic methods for par4 antagonist therapy
WO2016134450A1 (en) 2015-02-26 2016-09-01 Université de Montréal Imidazopyridazine and imidazothiadiazole compounds
US9789087B2 (en) 2015-08-03 2017-10-17 Thomas Jefferson University PAR4 inhibitor therapy for patients with PAR4 polymorphism
US9963466B2 (en) 2016-03-07 2018-05-08 Vanderbilt University Substituted 5-membered heterocyclic analogs as protease activated receptor 4 (PAR-4) antagonists
US20190119300A1 (en) * 2016-04-18 2019-04-25 Vanderbilt University Substituted and fused 6-membered protease activated receptor 4 (par-4) antagonists
WO2019149205A1 (zh) * 2018-01-31 2019-08-08 江苏恒瑞医药股份有限公司 苯并杂芳基类衍生物、其制备方法及其在医药上的应用
CN110218218B (zh) * 2018-03-01 2022-04-08 江苏恒瑞医药股份有限公司 苯并呋喃类衍生物、其制备方法及其在医药上的应用
CN110627817B (zh) * 2018-06-25 2022-03-29 中国药科大学 咪唑并环类par4拮抗剂及其医药用途
CN111349105B (zh) * 2018-12-24 2023-04-07 江苏恒瑞医药股份有限公司 苯并呋喃类衍生物、其制备方法及其在医药上的应用
CN111362970A (zh) * 2018-12-25 2020-07-03 天津药物研究院有限公司 苯并呋喃类衍生物及其制备方法和用途
US12077607B2 (en) 2021-09-23 2024-09-03 University Of Utah Research Foundation Functional and therapeutic effects of PAR4 cleavage by cathepsin G
CN117285527A (zh) * 2023-09-25 2023-12-26 中国药科大学 一种噌啉类par4拮抗剂及其医药应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0667345A1 (en) * 1994-02-14 1995-08-16 Yung Shin Pharm. Ind. Co. Ltd. 1-Benzyl-3-(substituted aryl)-condensed pyrazole derivatives as inhibitors of platelet aggregation
WO2001058930A1 (en) * 2000-02-09 2001-08-16 Zymogenetics, Inc. Par4 peptides and polypeptides
WO2001094411A1 (en) * 2000-06-05 2001-12-13 The Regents Of The University Of California Peptides modulating protease activated receptors and methods of using same
EP1166785A1 (en) * 2000-06-19 2002-01-02 Yung Shin Pharmeutical Ind. Co., Ltd. Use of pyrazole derivatives for inhibiting thrombin-induced platelet aggregation
WO2003033515A1 (en) * 2001-10-15 2003-04-24 Corixa Corporation Compositions and methods for the therapy and diagnosis of acne vulgaris

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE602004006529T2 (de) 2003-10-31 2008-01-31 Janssen Pharmaceutica N.V. Phenoxyessigsäure-derivate als peroxisom-proliferator-aktivierte rezeptor (ppar) dual-agonisten

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0667345A1 (en) * 1994-02-14 1995-08-16 Yung Shin Pharm. Ind. Co. Ltd. 1-Benzyl-3-(substituted aryl)-condensed pyrazole derivatives as inhibitors of platelet aggregation
WO2001058930A1 (en) * 2000-02-09 2001-08-16 Zymogenetics, Inc. Par4 peptides and polypeptides
WO2001094411A1 (en) * 2000-06-05 2001-12-13 The Regents Of The University Of California Peptides modulating protease activated receptors and methods of using same
EP1166785A1 (en) * 2000-06-19 2002-01-02 Yung Shin Pharmeutical Ind. Co., Ltd. Use of pyrazole derivatives for inhibiting thrombin-induced platelet aggregation
WO2003033515A1 (en) * 2001-10-15 2003-04-24 Corixa Corporation Compositions and methods for the therapy and diagnosis of acne vulgaris

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JPN6016023672; Ｔ．Ｒ．Ｆａｒｕｑｉ，　ｅｔ　ａｌ．，　Ｊ　Ｂｉｏｌ　Ｃｈｅｍ．，　２０００，　２７５（２６），　ｐｐ１９７２８-１９７３４ *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015514808A (ja) * 2012-04-26 2015-05-21 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 血小板凝集を治療するためのプロテアーゼ活性化受容体４（ｐａｒ４）阻害剤としてのイミダゾチアジアゾールおよびイミダゾピラジン誘導体

Also Published As

Publication number Publication date
CA2871640A1 (en) 2013-10-31
EP2841448A1 (en) 2015-03-04
US8927688B2 (en) 2015-01-06
US20160304560A1 (en) 2016-10-20
CN104411713A (zh) 2015-03-11
MX2014012803A (es) 2015-01-15
US20130289238A1 (en) 2013-10-31
BR112014026644A2 (pt) 2017-06-27
US9303065B2 (en) 2016-04-05
EA201491959A1 (ru) 2016-05-31
US9605024B2 (en) 2017-03-28
US20150158910A1 (en) 2015-06-11
WO2013163248A1 (en) 2013-10-31

Similar Documents

Publication Publication Date Title
US9303065B2 (en) PAR4 agonist peptides
EP3632919B1 (en) Pharmaceutical compoisitions comprising imidazothiadiazole and imidazopyridazine derivatives as protease activated receptor 4 (par4) inhibitors for treating platelet aggregation
JP6181744B2 (ja) 血小板凝集を治療するためのプロテアーゼ活性化受容体４（ｐａｒ４）阻害剤としてのイミダゾチアジアゾール誘導体
EP2855489B1 (en) Imidazothiadiazole and imidazopyridazine derivatives as protease activated receptor 4 (par4) inhibitors for treating platelet aggregation
KR102492715B1 (ko) 모노시클릭 헤테로아릴 치환된 화합물
EP3262053B1 (en) Imidazothiadiazole compounds as par4-inhibitors
US9617279B1 (en) Imidazooxadiazole compounds
RU2329273C2 (ru) Химерные аналоги лигандов соматостатиновых и допаминовых рецепторов, фармацевтические композиции на их основе и способы воздействия на рецепторы соматостатина и/или допамина
US9598419B1 (en) Imidazotriazine and imidazodiazine compounds
EP3371196A1 (en) Heterocyclic compounds as inhibitors of platelet aggregation
WO2016138199A1 (en) Benzothiazole and benzothiophne compounds
JP2002504490A (ja) トロンビン受容体アンタゴニストとしてのアゾールペプチド模倣体
HK1203953B (en) Imidazothiadiazole and imidazopyrazine derivatives as protease activated receptor 4 (par4) inhibitors for treating platelet aggregation

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150630

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20150630

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20160218

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160621

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160908

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20170221